JACK NATHAN MEDICAL CORP (JNH.CA) Fundamental Analysis & Valuation

TSX-V:JNH • CA4663771083

Current stock price

0.01 CAD
+0.01 (+100%)
Last:

This JNH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. JNH.CA Profitability Analysis

1.1 Basic Checks

  • JNH had negative earnings in the past year.
  • JNH had a negative operating cash flow in the past year.
  • In the past 5 years JNH always reported negative net income.
  • In the past 5 years JNH always reported negative operating cash flow.
JNH.CA Yearly Net Income VS EBIT VS OCF VS FCFJNH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M -8M -10M

1.2 Ratios

  • JNH's Return On Assets of -155.33% is on the low side compared to the rest of the industry. JNH is outperformed by 81.25% of its industry peers.
Industry RankSector Rank
ROA -155.33%
ROE N/A
ROIC N/A
ROA(3y)-87.41%
ROA(5y)-87.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JNH.CA Yearly ROA, ROE, ROICJNH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600 800

1.3 Margins

  • JNH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JNH.CA Yearly Profit, Operating, Gross MarginsJNH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200

0

2. JNH.CA Health Analysis

2.1 Basic Checks

  • JNH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for JNH has been increased compared to 1 year ago.
  • JNH has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for JNH is higher compared to a year ago.
JNH.CA Yearly Shares OutstandingJNH.CA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
JNH.CA Yearly Total Debt VS Total AssetsJNH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -9.28, we must say that JNH is in the distress zone and has some risk of bankruptcy.
  • JNH has a worse Altman-Z score (-9.28) than 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.28
ROIC/WACCN/A
WACC4.64%
JNH.CA Yearly LT Debt VS Equity VS FCFJNH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

  • A Current Ratio of 0.35 indicates that JNH may have some problems paying its short term obligations.
  • JNH's Current ratio of 0.35 is on the low side compared to the rest of the industry. JNH is outperformed by 68.75% of its industry peers.
  • JNH has a Quick Ratio of 0.35. This is a bad value and indicates that JNH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.35, JNH is doing worse than 68.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.35
Quick Ratio 0.35
JNH.CA Yearly Current Assets VS Current LiabilitesJNH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

3

3. JNH.CA Growth Analysis

3.1 Past

  • JNH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.59%.
  • Looking at the last year, JNH shows a very strong growth in Revenue. The Revenue has grown by 52.74%.
  • JNH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 45.61% yearly.
EPS 1Y (TTM)-29.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.17%
Revenue 1Y (TTM)52.74%
Revenue growth 3Y70.65%
Revenue growth 5Y45.61%
Sales Q2Q%6.27%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JNH.CA Yearly Revenue VS EstimatesJNH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 5M 10M 15M

0

4. JNH.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • JNH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JNH.CA Price Earnings VS Forward Price EarningsJNH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JNH.CA Per share dataJNH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. JNH.CA Dividend Analysis

5.1 Amount

  • No dividends for JNH!.
Industry RankSector Rank
Dividend Yield N/A

JNH.CA Fundamentals: All Metrics, Ratios and Statistics

JACK NATHAN MEDICAL CORP

TSX-V:JNH (6/6/2025, 7:00:00 PM)

0.01

+0.01 (+100%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners36.27%
Ins Owner ChangeN/A
Market Cap871.00K
Revenue(TTM)26.61M
Net Income(TTM)-10.34M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.31
BVpS-0.14
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -155.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-87.41%
ROA(5y)-87.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 159.45%
Cap/Sales 7.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.35
Quick Ratio 0.35
Altman-Z -9.28
F-Score3
WACC4.64%
ROIC/WACCN/A
Cap/Depr(3y)257.56%
Cap/Depr(5y)269.84%
Cap/Sales(3y)15.97%
Cap/Sales(5y)13.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)52.74%
Revenue growth 3Y70.65%
Revenue growth 5Y45.61%
Sales Q2Q%6.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-79.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-299.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-538.38%
OCF growth 3YN/A
OCF growth 5YN/A

JACK NATHAN MEDICAL CORP / JNH.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of JACK NATHAN MEDICAL CORP (JNH.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to JNH.CA.


What is the valuation status for JNH stock?

ChartMill assigns a valuation rating of 0 / 10 to JACK NATHAN MEDICAL CORP (JNH.CA). This can be considered as Overvalued.


How profitable is JACK NATHAN MEDICAL CORP (JNH.CA) stock?

JACK NATHAN MEDICAL CORP (JNH.CA) has a profitability rating of 0 / 10.


What is the financial health of JACK NATHAN MEDICAL CORP (JNH.CA) stock?

The financial health rating of JACK NATHAN MEDICAL CORP (JNH.CA) is 0 / 10.